Blackstone Backs Boston Scientific Heart Pump
Blackstone Life Sciences will provide up to $455 million to co-fund development of Boston Scientific's Vitalyst miniature heart pump.
Updated on Nov. 5, 2026 in Heart Disease
Blackstone Life Sciences agreed to provide up to $455 million to co-fund development of Boston Scientific's Vitalyst, a miniature heart pump providing temporary mechanical circulatory support. Blackstone disclosed the agreement on Monday, and Boston Scientific shifted the device's focus to acute myocardial infarction cardiogenic shock.
Why it matters
The agreement shifts financial risk for developing a temporary heart-support device to an outside investor while the target patient population moves toward a sicker group. The change follows research reporting that a competing pump failed to lower major adverse events in complex PCI patients.
Blackstone may receive up to 2.5 times its $455 million funding through milestone payments plus royalties on net sales, and Boston Scientific expects payments to begin in 2030. The temporary percutaneous ventricular assist device market is projected to exceed $3 billion by 2035, though the source does not say whether Vitalyst will reach that market.
The players
Boston Scientific
A Massachusetts-based medical device company that develops cardiovascular products, including the Vitalyst heart pump.
Blackstone Life Sciences
The life sciences investment arm of Blackstone, a major global alternative asset manager.
Johnson & Johnson
A multinational healthcare company whose Impella heart pump was the subject of March research on complex PCI patients.
The details
Vitalyst uses a magnetically driven impeller and a catheter and motor design intended to improve positional stability and reduce hemolysis. Boston Scientific's CEO called the device the largest investment the company has made, and the FDA has approved a Vitalyst PCI study.
Timeline
March 2026: Research reported that J&J's Impella heart pump failed to lower major adverse events in complex PCI patients.
May 2025: Boston Scientific's CEO called Vitalyst the largest investment the company has made at a Bernstein event.
November 2, 2026: The third-quarter earnings call discussed the focus shift.
November 3, 2026: Blackstone disclosed the $455 million agreement.
2030: Boston Scientific expects to begin making payments to Blackstone.
Health Landscape
Boston Scientific's redirection of Vitalyst away from high-risk PCI patients follows research showing J&J's Impella heart pump did not lower major adverse events in complex PCI patients. The move reflects how evolving trial evidence is redirecting the temporary mechanical circulatory support market toward cardiogenic shock.
The device is designed for patients experiencing cardiogenic shock during a heart attack, and its development may affect future treatment options for that group. Patients and clinicians will not see a changed treatment until the device receives regulatory approval, which the source does not date.
The takeaway
Investors are increasingly financing high-risk medical devices through milestone-based deals, which shift development costs while leaving commercial outcomes uncertain. Readers following heart-device news should watch for FDA decisions on Vitalyst's study and any changes in the cardiogenic shock market.
What happens next
Boston Scientific expects to begin making milestone payments to Blackstone in 2030, a date that will determine when the financing obligations take effect.
Further reading
Explore more on Heart Disease to see how temporary heart-support devices fit into cardiac care.
Source note: This article includes information reported by MedTech Dive.
